Market Overview
- The Global Gout Therapeutics Market is expected to grow at a high CAGR during the forecasting period (2020-2027).
- Gout s a type of inflammatory arthritis caused by the overabundance of uric acid in the body which is due to either producing too much or excreting too little. Gout can be acute and chronic. Acute gout mostly affects the major extremity joint, with the small joints of the hands and feet the most affected. In chronic gout, hard swellings (known as tophi) can form on the joints which are made of uric acid and grow large, even to the point of breaking through the skin.
Download free sample: https://www.datamintelligence.com/download-sample/gout-therapeutics-market
Market Dynamics
- The global gout therapeutics market is impacted by several factors such as the rising prevalence of gout globally due to change in lifestyle, increasing alcohol consumption, increasing obesity & kidney diseases, high purine diet, and consumption of several medications such as diuretics.
- Gout is the most common form of inflammatory arthritis, characterized by painful and disabling acute attacks. It is caused by hyperuricemia and the deposition of urate crystals, in and around the joints. Long-standing untreated hyperuricemia can lead to chronic arthritis, joint damage, tophi formation, and urate nephropathy. According to the Australian Bureau of Statistics and National Health Survey 2017-2018, estimated that 187,000 Australians (0.8% of the population) suffer from gout conditions. Gout is more common in males than females, almost 9 in 10 (87%) people with gout are males. Hence, the demand for your treatment is increasing, which is expected to show growth over the forecast period.
- Also, increasing government initiatives and awareness towards gout cause and treatment is expected to boost the growth of the market. For instance, in May 2016, the Arthritis Foundation and Takeda Pharmaceuticals USA Inc. launched the Let’s Speak Gout program, which offers tools for health care professionals and patients to make more effective gouty arthritis management a priority.
- In May 2018, Horizon Pharma plc marked Gout Awareness Day by launching Gout Revealed, which was created to spotlight real-life stories of people living with uncontrolled gout. People living with uncontrolled gout gets the opportunity to share their own story through the website, which will be updated throughout the year to help educate others.
- Also, rising research and development to introduce new gout treatment is driving the growth of the market over the forecast period. For instance, on October 29th, 2019, Researchers at the Washington State University Health Sciences Spokane and elsewhere have identified a new therapeutic target for the treatment of gout. The research lays the foundation for the development of new treatment strategies that could significantly improve the quality of life of millions of people around the world who suffer from the condition. In the United States alone, gout affects an estimated 8.3 million people or about 4 percent of the population.
- With the ongoing COVID-19 pandemic, several companies are testing their drugs for its treatment. For instance, on June 22nd, 2020, anti-viral drug Favipiravir (Fabiflu) was approved for the treatment of mild to moderate COVID-19 patients will be commercialized full scale in a week, says drugmaker Glenmark Pharmaceuticals. The Drug Controller General of India approved the anti-viral for 'restricted emergency use' for treatment of mild to moderate cases, which accounts for a majority of COVID-19 infections.
- However, the growth of the market is likely to hamper by side effects caused by grout drugs. For instance, the side effects of allopurinol include rash and low blood counts. Febuxostat side effects include rash, nausea, reduced liver function, and an increased risk of heart-related death. Also, the side effects of corticosteroids may include mood changes, increased blood sugar levels, and elevated blood pressure.
Segment Analysis
- By drug class, the gout therapeutics market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), antihyperuricemic agents (urate-lowering drugs), corticosteroids, colchicine, and others. Among these, the antihyperuricemic agent's segment is expected to grow with the highest CAGR over the forecast period. Some of the most common urate-lowering drugs used are xanthine oxidase inhibitors (allopurinol and febuxostat), uricases (pegloticase and rasburicase), and uricosuric medications (benzbromarone, probenecid, and sulfinpyrazone). With rising preference and for these drugs for the treatment of gout is boosting the growth of the market over the forecast period.
- On the other hand, the NSAIDs, corticosteroids, and colchicine are majorly used to treat acute gout. Non-steroidal anti-inflammatory drugs (NSAIDs) are estimated to dominate the gout therapeutics market in 2019, owing to the availability of these drugs at a lower cost compared to other drugs, a high level of penetration of drugs, and the ability to relieve pain in case of an acute gout attack. NSAIDs decrease pain and swelling. Some NSAIDs are available over-the-counter, like ibuprofen and naproxen sodium. Stronger NSAIDs like indomethacin and celecoxib are prescribed by the doctor.
- Colchicine is considered to be second-line therapy, used in patients unable to tolerate NSAIDs. These drugs have the ability to inhibit acute inflammatory response by restraining neutrophil adhesion, chemotaxis, and motility. On March 2nd, 2020, Avion Pharmaceuticals launched the Gloperba (colchicine, a ready-to-use solution for oral administration for prophylaxis of gout flares in adults. The approval was based on evidence from published literature supporting the efficacy of colchicine in patients with chronic gout. In 2 randomized clinical trials, the treatment with colchicine 0.6mg twice daily was associated with a decrease in the frequency of gout flares.
- By disease type, the chronic gout is dominating the gout therapeutics market. This segment encompasses urate-lowering agents such as xanthine oxidase inhibitor and uricosuric agents. The introduction of urate-lowering drugs and the expected entry of pipeline drugs are likely to drive the market at the fastest rate during the forecast period.
Geographical Analysis
- North America is dominating the global gout therapeutics market accounting for the largest market share in 2019, owing to the large presence of major players, high demand for gout therapy, and high cost of branded pharmaceuticals in the U.S. Also, the research and development of new drugs for the treatment of gout is expected to show dominance over the forecast period. In June 2020, Pharma major Dr. Reddy's Laboratories has launched the generic Colchicine tablets which are used for the prevention and treatment of acute gout flares in the US market.
- Also, in December 2019 Selecta Biosciences, Inc., a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, completed the patient enrollment in the six-month, head-to-head, Phase 2 COMPARE clinical trial. The trial is evaluating the superiority of a once-monthly dose of Selecta’s lead product candidate, SEL-212 (ImmTOR + pegadricase), versus a bi-weekly dose of pegloticase, the current FDA-approved uricase therapy for adult patients with chronic refractory gout.
- The Asia Pacific region is expected to grow at the fastest growth rate over the forecast period owing to the diversified patient pool, growing investment by major players with local manufacturers and hospital chains in growing countries such as India, China, South Korea, and other South Asian countries. According to the Australian Institute of Health and Welfare, in 2015-2016, gout cost the Australian health system an estimated USD 176.5 million, representing 1.4% of disease expenditure on musculoskeletal conditions and 0.2% of total disease expenditure. Also, changing lifestyles with a rising prevalence of smoking & alcohol consumption is expected to boost the incidence of gout over the period.
Competitive Analysis
- The gout therapeutics market is fragmented and highly competitive and consists of several major players. The market share is dominated by few major players and few emerging companies which are expected to enter the market over the forecast period. Some of the major players of the market are Horizon Therapeutics plc, Lannett Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Ltd, Mylan, among others. The key players are adopting various growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Gout Therapeutics market globally. For instance,
- On March 2nd, 2020, Avion Pharmaceuticals launched Gloperba (colchicine) oral solution for prophylaxis of gout flares in adults.
- In January 2020, US-based Novadoz Pharmaceuticals has received FDA approval for their generic version of Febuxostat 40mg and 80mg tablets. The approved product is AB-rated to the brand Uloric©, marketed by Takeda Pharmaceuticals America, Inc.
View full report: https://www.datamintelligence.com/research-report/gout-therapeutics-market
Enquiry before buying: https://www.datamintelligence.com/enquiry/gout-therapeutics-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com
This report studies the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market, covering market size for segment by type (5-HT3 Inhibitors, NK1 Inhibitors, etc.
), by Sales Channel (Direct Channel, Distribution Channel), by player (Merck, Eisai, Mundipharma, Qilu Pharma, Teva, etc.)
and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa).
Since the pandemic of COVID-19 is still raging, The COVID-19 will have a certain impact on this global market.
This research covers COVID-19 impacts on the upstream, midstream and downstream industries.
Moreover, this research provides an in-depth market evaluation by highlighting information on various aspects covering market dynamics like drivers, barriers, opportunities, threats, and industry news & trends.Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-chemotherapy-induced-nausea-vomiting-drugs-2021-2030-429 This report provides detailed historical analysis of global market for Chemotherapy Induced Nausea and Vomiting (CINV) Drugs from 2015-2020, and provides extensive market forecasts from 2021-2030 by region/country and subsectors.
Global SERD Therapeutics Market to Reach $4.0 Billion by 2030Market Report Coverage - SERD TherapeuticsMarket Segmentation• By Product – Faslodex, RAD1901, GDC-9545, AZD9833, SAR439859, Other Generics• By Application – First-line treatment and second-line treatmentRegional Segmentation• North America – U.S., Canada• Europe – Germany, France, U.K., Italy, Spain, and Rest-of-Europe• Asia-Pacific – China, Japan, and Rest-of-Asia-Pacific (RoAPAC)• Rest-of-the-WorldGrowth Drivers• Rising incidence of breast cancer• Advanced route of administration: oral drug deliveryMarket Challenges• Resistance to endocrine therapyMarket Opportunities• SERDs as combination therapy• Therapeutic potential in different types of cancerKey Companies ProfiledAstraZeneca, Plc, Novartis AG, Sanofi S.A, Hofmann-la Roche AG, G1 Therapeutics, Zentalis Pharmaceuticals, Zenopharm LLC, Radius Health, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd, InventisBio, Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, HBT Labs, and Amneal pharmaceuticals, Inc.Key Questions Answered in this Report:• What is SERD therapy?• How did the SERD therapy market evolve, and what is its scope in the future?• What are the major market drivers, restraints, and opportunities in the global SERD therapeutics market?• What are the key developmental strategies that are being implemented by the key players to sustain this market?• What is the impact of generics on branded therapy?• What is the impact of COVID-19 on this market?• What are the guidelines implemented by different government bodies to regulate the approval of products to be used in breast cancer treatment?• How is SERD therapy being utilized for the treatment of postmenopausal women with breast cancer?• What was the market size of the leading segments and sub-segments of the global SERD therapeutics market in 2019?• How will the industry evolve during the forecast period 2020-2030?• What will be the growth rate of the SERD therapeutics market during the forecast period?• How will each segment of the global SERD therapeutics market grow during the forecast period, and what will be the revenue generated by each segment by the end of 2030?• Which product segment and application segment are expected to register the highest CAGR for the global SERD therapeutics market?• What is the market size of the SERD therapeutics market in different countries of the world?• Which geographical region is expected to contribute to the highest sales in the global SERD therapeutics market?• What is the regulatory framework for the SERD therapeutics market in different regions?• What are the key strategies incorporated by the players of the global SERD therapeutics market to sustain the competition and retain their supremacy?Market OverviewThe unmet clinical benefits and quest for novel therapies with better efficacy and safety to improve the quality of life in patients living with breast cancer treatment, complete estrogen receptor inhibition, and resistance to multiple endocrine therapies led to the discovery of SERD therapies.SERD therapy has been extensively accepted and used as both monotherapy and in combination with other therapeutic agents.The potential of SERD therapy in breast cancer treatment is yet to be fully discovered, thus leaving a substantial scope of innovation and research in the field.The global SERD therapeutics market was valued at $1000.2 million in 2019 and is expected to reach $4085.0 million by 2030, witnessing a CAGR of 16.66% during the forecast period 2020-2030.
The market growth can mainly be attributed to the increasing breast cancer incidence and mortality worldwide, increasing number of relapsed or refractory cases in breast cancer, unmet clinical benefits with existing breast cancer treatments targeting hormone receptor-positive metastatic breast cancer, eased route of administration and dosage exposure, rising focus of the key players on research and development (R) activity for new product launch, and increased government and private funding for improved safety and outcomes provided by SERD therapy.The global SERD therapeutics market is expected to witness high growth in the future.
The increasing global breast cancer incidence and mortality and increased demand for endocrine therapies that cure chronic conditions completely and improve the quality of life of patients are the major factors anticipated to contribute to the growth of the global SERD therapeutics market.Furthermore, the increasing number of relapsed or refractory cases in breast cancer, unmet clinical benefits with existing breast cancer treatments targeting hormone receptor-positive metastatic breast cancer, painful route of administration and limited dosage exposure will augment the SERD therapeutics market.Also, the increased use of SERDs as combination therapy with other endocrine agents and rising focus of the key players on research and development (R) activity for new product launch is expected to drive the market.Rise in government and private funding for improved safety and outcomes provided by SERD therapy are additional factors propelling the growth.Within the research report, the market is segmented based on therapy type, product, region.
Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe global SERD therapeutics market is currently dominated by Sandoz, Mylan N.V., Glenmark Pharmaceuticals, Dr. Reddy’s Laboratories, Accord Healthcare, and Teva Pharmaceuticals Industries Ltd.
The market dominance of these companies can be attributed to cost-effective generic fulvestrant availability in the market.
As of 2018, AstraZeneca Plc was the only company to offer SERD therapy in the global SERD therapeutics market.
